Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:VIVO
Previous Symbol
CUSIP58958410
Phone513-271-3700
Debt
Debt-to-Equity Ratio0.27
Current Ratio5.73
Quick Ratio3.89
Price-To-Earnings
Trailing P/E Ratio26.23
Forward P/E Ratio25.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$213.57 million
Price / Sales3.85
Cash Flow$1.0469 per share
Price / Cash18.54
Book Value$4.02 per share
Price / Book4.83
Profitability
EPS (Most Recent Fiscal Year)$0.74
Net Income$23.84 million
Net Margins11.17%
Return on Equity18.21%
Return on Assets12.51%
Miscellaneous
Employees640
Outstanding Shares42,400,000
Market Cap$826.71 million
OptionableOptionable
Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience announced a quarterly dividend on Friday, November 9th. Shareholders of record on Monday, November 19th will be given a dividend of $0.125 per share on Friday, November 30th. This represents a $0.50 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Friday, November 16th. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its earnings results on Thursday, November, 8th. The company reported $0.20 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.16 by $0.04. The business earned $213.60 million during the quarter, compared to the consensus estimate of $51.11 million. Meridian Bioscience had a net margin of 11.17% and a return on equity of 18.21%. The company's revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS. View Meridian Bioscience's Earnings History.
When is Meridian Bioscience's next earnings date?
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience issued an update on its FY 2019 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.77. The company issued revenue guidance of $217.842-222.114 million, compared to the consensus revenue estimate of $217.65 million.Meridian Bioscience also updated its guidance to EPS.
What price target have analysts set for VIVO?
1 analysts have issued twelve-month price objectives for Meridian Bioscience's shares. Their predictions range from $16.00 to $16.00. On average, they anticipate Meridian Bioscience's share price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for Meridian Bioscience.
What is the consensus analysts' recommendation for Meridian Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience.
Has Meridian Bioscience been receiving favorable news coverage?
News articles about VIVO stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Meridian Bioscience earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Achieve Life Sciences (ACHV) and Arca Biopharma (ABIO).
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
- Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
- Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 49)
- Mr. Lawrence J. Baldini, Exec. VP of Global Operations (Age 59)
- Dr. Lourdes G. Weltzien, Exec. VP of Life Science Bus. Unit
Who are Meridian Bioscience's major shareholders?
Meridian Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.69%), Renaissance Technologies LLC (6.61%), Dimensional Fund Advisors LP (4.45%), Systematic Financial Management LP (2.69%), Bank of New York Mellon Corp (1.94%) and JPMorgan Chase & Co. (1.38%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Which institutional investors are selling Meridian Bioscience stock?
VIVO stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Credit Suisse AG, Alambic Investment Management L.P., Russell Investments Group Ltd., Greylin Investment Mangement Inc., JPMorgan Chase & Co., JPMorgan Chase & Co. and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. View Insider Buying and Selling for Meridian Bioscience.
Which institutional investors are buying Meridian Bioscience stock?
VIVO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Renaissance Technologies LLC, Matarin Capital Management LLC, Dimensional Fund Advisors LP, Los Angeles Capital Management & Equity Research Inc., Ronna Sue Cohen and Victory Capital Management Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy shares of Meridian Bioscience?
Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of VIVO stock can currently be purchased for approximately $19.41.
How big of a company is Meridian Bioscience?
Meridian Bioscience has a market capitalization of $826.71 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.
What is Meridian Bioscience's official website?
How can I contact Meridian Bioscience?
Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.
MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
